Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > xB3-004
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(192)
•••
Comment by craighenryon Dec 28, 2022 5:37pm
89 Views
Post# 35194417

RE:xB3-004

RE:xB3-004
JDavenport wrote:

Bioasis got that preclinical MS study done. That means that in addition to the several agreements signed, Bioasis got one of its own programs, xB3-004, underway. Progranulin soon. (Timing is about right.)

But what happens then with those two? BDs? Or just one to cover them both?

What about xB3-001? My guess is that somebody is working on that, probably has been for a while. Go read DrDR's quotes about these things. She's just aching to spill the beans. But she can't. Partners can be twits about these things, as I have posted for ten years.

But, xB3 is the key. Potential partners can't get through the doors without the key.

Can't wait.

jd

 




Good "guess" nut job!!

Again, you are sooooo special for being able to "read between the lines"!!



I bet you were "just waiting " for this deal!!!!!!



LoloLoL



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities